Effect Study of the Recombinant Human Brain Natriuretic Peptide in Patients with Heart Failure Combined with Hypotension

Objective: This paper aims to investigate the effect of applying recombinant human brain natriuretic peptide in patients with heart failure combined with hypotension. Recombinant human brain natriuretic peptide is a synthetic polypeptide drug that is primarily used to treat acute heart failure. Its mechanism of action closely mimics that of human endogenous brain natriuretic peptide. By binding to receptors on cardiomyocytes, it exerts its pharmacological effects. Methods: For the study, 76 heart failure patients with hypotension were selected from our hospital between May 2022 and June 2023. These patients were divided into two groups: a control group and an observation group, each comprising 38 patients. The control group received dopamine treatment, while the observation group was treated with recombinant brain natriuretic peptide. The objective was to compare the effects of the treatments in both groups by analyzing cardiac function indices and levels of vasoactive substances to identify any significant differences in outcomes. Results: The overall response rate of the patients in the observation group and the control group was 94.74% and 73.68%, significantly higher as compared with the observation group (P 0.05). After the following treatment, BNP, ANNP and urine output in the observation group were significantly different compared with the control group, of the statistical significance (P Conclusion: For the treatment of heart failure patients with hypotension, the clinical application of recombinant human brain natriuretic peptide is the most ideal, and significantly improves the cardiac function of patients, which is worth popularizing.

Lyophilized recombinant human brain natriuretic peptide for chronic heart failure:Effects on cardiac function and inflammation

BACKGROUND Chronic heart failure(CHF)is a serious and prevalent condition characterized by impaired cardiac function and inflammation.Standard therapy for CHF has limitations,prompting the exploration of alternative treatments.Recombinant human brain natriuretic peptide(BNP)has emerged as a potential therapy,with evidence suggesting that it can improve cardiac function and reduce inflammation in patients with CHF.However,further research is required to determine the efficacy and safety of lyophilized recombinant human BNP in CHF patients and its impact on microinflammatory status.This study aimed to investigate the effects of lyophilized recombinant human BNP therapy on CHF patients’cardiac function and microinflammatory status.AIM To investigate the effects of freeze-dried recombinant human BNP therapy on cardiac function and microinflammatory status in patients with CHF.METHODS In total,102 CHF patients admitted to our hospital from January 2021 to January 2022 were randomly assigned to control and observation groups(n=51 patients/group).The control patients were treated with standard HF therapy for 3 d,whereas the observational patients were injected with the recombinant human BNP for 3 d.Clinical efficacy,inflammatory factor levels,myocardial damage,cardiac function before and after the treatment,and adverse reactions during treatment were compared between the two groups.RESULTS The overall clinical efficacy was higher in the observation group than in the control group.Compared with baseline,serum hypersensitive C-reactive protein,N-terminal proBNP,and troponin I level,and physical,emotional,social,and economic scores were lower in both groups after treatment,with greater reductions in levels and scores noted in the observation group than in the control group.The overall incidence of adverse reactions in the observation group was not significantly different compared with that in the control group(P>0.05).CONCLUSION Freeze-dried recombinant human BNP therapy can improve heart function and enhance microinflammatory status,thereby improving overall quality of life without any obvious side effects.This therapy is safe and reliable.

Lyophilized recombinant human brain natriuretic peptide: A promising therapy in patients with chronic heart failure

Lyophilized recombinant brain natriuretic peptide(BNP)is an exogenous peptide synthesized by artificial recombination technology,with a similar structure and similar physiological effects with the endogenous natriuretic peptide secreted by the human body.It’s main mechanism of action is to increase cyclic guanosine monophosphate by binding with its corresponding receptor in the body,regulating,thus,the imbalance of the vascular system and cardiac hemodynamics,improving the heart’s pumping capacity,and inhibiting sympathetic excitability and myocardial remodeling.Moreover,it can promote mitochondrial metabolism and enhance the use of adenosine triphosphate in cardiomyocytes.In the present study,102 chronic heart failure(HF)patients were randomly assigned to a control and an observation group consisting of 51 patients each.Patients of the control group were treated with standard HF therapy for 3 d including oral metoprolol tartrate tablets,spironolactone,and olmesartanate while patients of the observation group were administered the recombinant human BNP injection for the same time-period,plus the standard HF therapy.The recombinant human BNP group(observation group)demonstrated better physical,emotional,social,and economic scores,as well as cardiac and inflammatory biomarkers such as serum hypersensitive C-reactive protein,N-terminal pro BNP and troponin I levels,compared to the control group.Moreover,cardiac function was also improved,as left ventricular ejection fraction and stroke volume were significantly higher in the observation group than in the control group.Interestingly,adverse reactions were not different between the 2 groups.However,these results are not generalizable and the need of large multicenter randomized controlled trials examining the safety and efficacy of recombinant human BNP in HF patients is of major importance.

Clinical study of recombinant human brain natriuretic peptide in patients with acute myocardial infarction complicating congestive heart failure

Objectives To observe the efficacy and safety of recombinant human brain natriuretic peptide(rh-BNP) on patients with acute myocardial infarction complicating congestive heart failure.Methods 40 patients with acute myocardial infarction complicated by congestive heart failure were randomly divided into control group and treatment group of 20 cases.The control group,15 cases of acute anterior myocardial infarction,5 cases of acute inferior wall myocardial infarction, 15 males and 5 females,aged 55-70 years,mean age 58±12 years;treated 16 cases of acute anterior myocardial infarction,4 cases of acute myocardial infarction,16 males and 4 females,aged 56-70 years,mean age 59±11 years;two groups of age,gender,severity of disease and vascular lesions no significant difference and comparable(P】0.05).Conventional group were given aspirin,clopidogrel, statins,Inotropic,diuretic and vasodilator therapy.In the con- ventional treatment group based on the use of recombinant human brain natriuretic peptide(new bios,Tibet Pharmaceutical Co.,Ltd.Chengdu Nuodikang biopharmaceutical production, usage:1.5μg/Kg intravenous injection(impact), then 0.0075μg-0.01μg/(kg·min)infusion rate).Continuous medication 72 h.The clinical symptoms observed for 3 days in patients before treatment and after treatment,heart rate,blood pressure and left ventricular ejection fraction (LVEF) and tumor necrosis factor(TNF-α),brain natriuretic peptide(BNP) levels were measured.Results In control group,8 cases markedly effect,5 cases effect and 7 cases no effect,the total effective rate was 65%;In treatment group,13 cases markedly effect,6 cases effect and 1 cases no effect,the total effective rate was 95%,compared with two groups P New bios treatment group significantly increased cardiac index(CI) in patients with heart failure and left ventricular ejection fraction(LVEF) than the control group(all P【0.05),further reduce the levels of tumor necrosis (TNF-α) and brain natriuretic peptide(BNP).Conclusions rh-BNP can improve symptoms and heart function,reduced plasma tumor necrosis factor(TNF-α) and BNP levels of acute myocardial infarction patients with congestive heart failure,the treatment safe and reliable.As small sample size observed,larger sample to be accumulated to further evaluate its efficacy and safety.

Effect of recombinant human brain natriuretic peptide on serum inflammatory factors, neuroendocrine hormones and cardiac function in patients with acute myocardial infarction complicated with heart failure

Objective:To investigate the effect of recombinant human brain natriuretic peptide (BNP) on inflammatory factors, neuroendocrine hormones and cardiac function indexes in patients with acute myocardial infarction complicated with heart failure.Methods:A total of91 cases of acute myocardial infarction with heart failure patients were divided into the control group (n=44) and observation group (n=47) according to the random data table, two groups of patients were given conventional treatment, based on this, the control group was given intravenous infusion of Nitroglycerin Injection treatment, the observation group received intravenous injection of recombinant human brain natriuretic peptide treatment, compared serum inflammatory factors, neuroendocrine hormone and cardiac function and other indexes of two groups before and after treatment.Results: there was no significant difference between the two groups before treatment. After treatment, the levels of TNF-α, hs-CRP, IL-6, MCP-1, LVESD and LVEDD in the two groups were significantly lower than those within the group before treatment, and the observation group was significantly lower than the control group;The two groups after treatment LVEF levels were significantly higher than those in the group before treatment, and the observation group was significantly higher than that of control group;the observation group after treatment PRA, Ang II and ALD and NE levels were significantly lower than those before treatment, and was significantly lower than the control group after treatment, the difference was significant, PRA, Ang, ALD and NE levels of control group before and after the treatment was no significant difference.Conclusion:recombinant human brain natriuretic peptide in the treatment of acute myocardial infarction with heart failure can effectively reduce the serum inflammatory factors and neuroendocrine hormone levels, improve heart function, and have a certain clinical value.

Differential effects of atrial and brain natriuretic peptides on human pulmonary artery:An in vitro study

BACKGROUND The prevalence of cardiovascular diseases,especially heart failure,continues to rise worldwide.In heart failure,increasing levels of circulating atrial natriuretic peptide(ANP)and brain natriuretic peptide(BNP)are associated with a worsening of heart failure and a poor prognosis.AIM To test whether a high concentration of BNP would inhibit relaxation to ANP.METHODS Pulmonary arteries were dissected from disease-free areas of lung resection,as well as pulmonary artery rings of internal diameter 2.5–3.5 mm and 2 mm long,were prepared.Pulmonary artery rings were mounted in a multiwire myograph,and a basal tension of 1.61gf was applied.After equilibration for 60 min,rings were pre-constricted with 11.21μmol/L PGF2α(EC80),and concentration response curves were constructed to vasodilators by cumulative addition to the myograph chambers.RESULTS Although both ANP and BNP were found to vasodilate the pulmonary vessels,ANP is more potent than BNP.pEC50 of ANP and BNP were 8.96±0.21 and 7.54±0.18,respectively,and the maximum efficacy(Emax)for ANP and BNP was-2.03 gf and-0.24 gf,respectively.After addition of BNP,the Emax of ANP reduced from-0.96gf to-0.675gf(P=0.28).CONCLUSION BNP could be acting as a partial agonist in small human pulmonary arteries,and inhibits relaxation to ANP.Elevated levels of circulating BNP could be responsible for the worsening of decompensated heart failure.This finding could also explain the disappointing results seen in clinical trials of ANP and BNP analogues for the treatment of heart failure.

恩格列净联合rhBNP治疗射血分数降低型心力衰竭的疗效

目的:探究恩格列净联合重组人脑利钠肽(rhBNP)治疗射血分数降低型心力衰竭(HFrEF)的疗效及对患者血清N-末端脑钠肽前体(NT-proBNP)、可溶性生长刺激表达基因2蛋白(sST2)和炎症因子的影响。方法:选取108例HFrEF患者为研究对象,根据治疗方式不同将患者分为对照组(n=54)和观察组(n=54)。对照组予以rhBNP治疗;观察组予以rhBNP联合恩格列净治疗。比较两组临床疗效及治疗前后心功能[左室射血分数(LVEF)、6 min步行试验(6MWT)、美国堪萨斯城心肌病患者生存质量表(KCCQ)]、心室重构[左室收缩末期内径(LVEDS)、左室舒张末期内径(LVEDD)]、血清NT-proBNP、sST2及炎症因子[肿瘤坏死因子α(TNF-α)、白细胞介素1β(IL-1β)、IL-6]水平。结果:观察组临床总有效率高于对照组(90.74%vs.74.07%,P<0.05)。治疗后,观察组LVEF、6MWT、KCCQ均高于对照组(P<0.05);LVEDS、LVEDD、NT-proBNP、sST2、TNF-α、IL-1β、IL-6水平均低于对照组(P<0.05)。两组不良反应发生率无统计学差异(P>0.05)。结论:恩格列净联合rhBNP治疗HFrEF的疗效和安全性均较好,可有效提高患者心功能,改善心室重构,降低血清NT-proBNP、sST和炎症因子水平。

恩格列净联合rhBNP治疗射血分数降低型心力衰竭的疗效及对患者心功能和血清FGF-21、sVEGFR-2水平的影响

目的探究恩格列净联合重组人脑利钠肽(rhBNP)治疗射血分数降低型心力衰竭(HFrEF)的疗效及对患者心功能和血清成纤维细胞生长因子-21(FGF-21)、可溶性血管内皮生长因子受体-2(sVEGFR-2)水平的影响。方法前瞻性选取2022年1月至2023年3月山东第一医科大学附属人民医院心内科收治的100例HFrEF患者为研究对象。按照随机数字表法将其分为对照组和观察组,每组各50例。对照组予以常规强心、利尿治疗及静脉泵入rhBNP,观察组在对照组基础上加用恩格列净。比较两组治疗前、治疗3个月后糖化血红蛋白(HbA1c)、总胆固醇、低密度脂蛋白胆固醇(LDL-C)、6 min步行距离测试(6MWD)、N末端脑钠肽前体(NT-proBNP)、左室射血分数(LVEF)及血清FGF-21、sVEGFR-2水平,并记录两组主要心血管不良事件(MACE)发生情况。结果观察组临床总有效率为94.00%,高于对照组(80.00%),差异有统计学意义(P<0.05)。治疗3个月后,观察组HbA1c水平为(5.34±1.51)%,低于对照组[(6.03±1.65)%],差异有统计学意义(P<0.05);两组患者的总胆固醇、LDL-C水平比较,差异均无统计学意义(P>0.05)。治疗3个月后,观察组LVEF、6MWD水平分别为(38.52±7.24)%、(493.66±47.79)m,均高于对照组[(34.02±8.06)%、(455.92±50.25)m],NT-proBNP水平为(4386.75±875.89)pg/mL,低于对照组[(4326.04±843.66)pg/mL],差异均有统计学意义(P<0.05)。治疗3个月后,观察组血清FGF-21水平为(54.93±12.51)pg/mL,低于对照组[(61.50±15.66)pg/mL],sVEGFR-2水平为(8.96±1.95)ng/mL,高于对照组[(8.14±1.67)ng/mL],差异均有统计学意义(P<0.05)。观察组与对照组MACE总发生率分别为6.00%、16.00%,差异无统计学意义(P>0.05)。结论在rhBNP治疗HFrEF的基础上加用恩格列净可明显提高临床疗效,改善患者心功能,降低HbA1c、FGF-21水平,并提高sVEGFR-2水平可能是其增效的作用机制。

rhBNP与沙库巴曲缬沙坦钠联合治疗对射血分数下降心力衰竭患者心功能及自主神经功能的影响

目的研究分析重组人脑利钠肽(Recombinant Human Brain Natriuretic Peptide,rhBNP)与沙库巴曲缬沙坦钠联合治疗对射血分数下降心力衰竭(Decreased Ejection Fraction Heart Failure,HFrEF)患者心功能及自主神经功能的影响。方法简单随机选取2022年8月—2023年8月漳州市第三医院收治的60例HFrEF患者作为研究对象,采用随机数表法分为两组,各30例。对照组予以沙库巴曲缬沙坦钠单药治疗,观察组予以rhBNP及沙库巴曲缬沙坦钠两药共治,比较两组患者的用药效果。结果观察组临床总有效率(93.33%)高于对照组(73.33%),差异有统计学意义(χ^(2)=4.320,P<0.05)。治疗后,观察组左室射血分数(Left Ventricular Ejection Fraction,LVEF)较对照组更高,左室舒张期后壁厚度(Left Ventricular Diastolic Posterior Wall Thickness,LVPWD)、左室舒张期内径(Left Ventricular Diastolic Diameter,LVEDD)均较对照组更低,差异有统计学意义(P均<0.05)。治疗后,观察组去甲肾上腺素(Norepinephrine,NE)、血管紧张素Ⅱ(AngiotensinⅡ,AngⅡ)及醛固酮水平均低于对照组,差异有统计学意义(P均<0.05)。两组患者不良反应发生率对比,差异无统计学意义(P>0.05)。结论rhBNP与沙库巴曲缬沙坦钠两药共治可提升对HFrEF患者的治疗效果,有效改善其心功能及自主神经功能,且安全可靠。

rhBNP联合地尔硫卓治疗对急性心肌梗死合并心力衰竭患者心率变异性及住院期间MACE发生率的影响

目的探究重组人B型钠尿肽(rhBNP)联合地尔硫卓对急性心肌梗死合并心力衰竭患者心率变异性(HRV)及住院期间不良心血管事件(MACE)发生率的影响。方法将182例急性心肌梗死合并心力衰竭患者随机分为对照组和观察组,对照组给予常规治疗,观察组在对照组基础上给予rhBNP联合地尔硫卓治疗;观察两组临床疗效,比较治疗前后心功能指标、HRV指标及相关实验室指标的变化,并统计患者住院期间MACE发生情况。结果观察组总治疗有效率为89.01%,高于对照组(P<0.05)。治疗后,两组LVEF均高于同组治疗前,LVEDV和LVESV均低于同组治疗前,且观察组LVEF高于对照组,LVEDV和LVESV低于对照组(P<0.05)。治疗后,对照组SDNN、SDANN、RMSSD及PNN50较治疗前均有所提高,仅SDNN和PNN50治疗前后比较有统计学意义(P<0.05);观察组治疗后上述指标均明显高于治疗前,且高于对照组(P<0.05)。治疗后,两组NT-proBNP、hs-CRP及Cr低于同组治疗前,且观察组上述指标低于对照组(P<0.05)。治疗期间,两组患者均未出现明显不良反应;住院期间,观察组MACE发生率为6.59%,低于对照组(P<0.05)。结论rhBNP联合地尔硫卓可明显改善急性心肌梗死合并心力衰竭患者心功能,提高HRV,降低MACE发生率,安全性高。

托伐普坦联合rhBNP治疗难治性心力衰竭的临床疗效

目的探究托伐普坦联合重组人脑利钠肽(rhBNP)治疗难治性心力衰竭的临床疗效及其对心功能、炎性因子水平的影响。方法80例难治性心力衰竭患者为研究对象,依据用药方法不同分为参照组和观察组,每组40例。参照组在常规治疗基础上应用托伐普坦片治疗,观察组在参照组基础上应用重组人脑利钠肽治疗。比较两组的治疗效果、心功能指标[左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)、左心室射血分数(LVEF)]、炎性因子[白细胞介素-6(IL-6)、超敏C反应蛋白(hs-CRP)]水平。结果观察组临床治疗总有效率95.00%高于参照组的77.50%,差异有统计学意义(P<0.05)。观察组LVEDD(50.15±2.11)mm、LVESD(37.54±3.05)mm、LVEF(56.42±2.67)%均明显优于参照组的(56.31±2.32)mm、(41.31±3.46)mm、(50.22±2.22)%,差异均有统计学意义(P<0.05)。治疗后,观察组hs-CRP(4.31±1.25)mg/L、IL-6(8.15±2.31)ng/L均低于参照组的(9.71±1.37)mg/L、(12.36±3.66)ng/L,差异均有统计学意义(P<0.05)。结论托伐普坦联合重组人脑利钠肽在难治性心力衰竭治疗中效果理想,可有效改善患者心功能指标,降低机体炎性因子水平,值得临床推广应用。

rhBNP联合沙库巴曲缬沙坦钠治疗冠心病心力衰竭的效果分析

目的分析重组人脑利钠肽(rhBNP)联合沙库巴曲缬沙坦钠对冠心病心力衰竭患者的疗效。方法选取2020年10月至2022年10月该院收治的冠心病心力衰竭患者240例,按不同治疗方案分为A组和R组,每组120例。A组在常规治疗基础上加用沙库巴曲缬沙坦钠片口服治疗,R组在常规治疗基础上采用rhBNP联合沙库巴曲缬沙坦钠片治疗,疗程均为4周。记录2组患者治疗1周后一般临床指标(包括收缩压、心率和平均每小时尿量)、治疗4周后心功能相关指标(包括左心室射血分数、左心室舒张末期内径和每搏输出量),以及血清线粒体偶联因子6、心锚重复蛋白、细胞黏附分子-1、醛固酮水平等。结果R组患者治疗1周后心率、收缩压均明显低于A组,平均每小时尿量明显高于A组,差异均有统计学意义(P<0.05);治疗4周后左心室射血分数、每搏输出量均明显高于A组,左心室舒张末期内径,以及血清线粒体偶联因子6、心锚重复蛋白、细胞黏附分子-1、醛固酮水平均明显低于A组,差异均有统计学意义(P<0.05)。结论rhBNP联合沙库巴曲缬沙坦钠可快速缓解冠心病心力衰竭患者临床症状,有效改善心功能,效果显著,值得借鉴。

rhBNP联合沙库巴曲缬沙坦对急性心力衰竭患者心功能及神经内分泌激素水平的影响

目的:探究联合使用重组人脑利钠肽(rhBNP)与沙库巴曲缬沙坦对急性心力衰竭(AHF)患者心功能及神经内分泌激素水平的影响。方法:选取兴山县人民医院2020~2021年收治的100例AHF患者为研究对象,按照简单随机化法将研究对象1∶1分为观察组50例和对照组50例,两组患者均常规使用扩血管药物进行降压治疗,对照组在此用药基础上加用沙库巴曲缬沙坦,观察组在对照组基础上加用rhBNP,比较两组治疗前、后心功能指标、神经内分泌细胞因子及炎性因子水平,两组用药后不良反应发生率的差异。结果:治疗后,两组左心室舒张末期容积(LVEDV),左心室收缩末期容积(LVESV)、血浆醛固酮(ALD)、心房钠尿肽(ANP)、心肌肌钙蛋白(cTnI)、白细胞介素-6及C反应蛋白水平均比治疗前下降,左心室射血分数(LVEF)比治疗前升高,且观察组LVEDV,LVESV、ALD、ANP、cTnI、白细胞介素-6及C反应蛋白水平比对照组更低,LVEF比对照组更高,差异均有统计学意义(P<0.05)。结论:rhBNP联合沙库巴曲缬沙坦对AHF患者的心功能有明显改善作用,可有效缓解心肌损伤,并能调节其神经内分泌系统,从而缓解炎性反应,药物方案安全性良好。

ARNI联合rhBNP治疗急性前壁心肌梗死介入术后心力衰竭疗效分析

目的探讨急性前壁心肌梗死介入术后合并心力衰竭患者早期接受小剂量沙库巴曲缬沙坦(ARNI)联合重组人脑利钠肽(rhBNP)治疗的疗效及安全性。方法选取2019年12月至2021年12月本院收治的急性前壁心肌梗死介入术后合并心力衰竭患者102例,对照组52例,观察组50例。对照组给予双联抗血小板聚集药物、利尿剂、β受体阻滞剂、醛固酮拮抗剂、血管紧张素抑制剂、rhBNP等常规治疗;观察组在对照组基础上,将血管紧张素抑制剂改为沙库巴曲缬沙坦小剂量起始治疗。观察两组患者心功能指标、肾功能、电解质、低血压发生率、生存质量、心衰再入院率等指标变化。结果治疗1周时,两组患者血浆N-末端脑利钠肽水平、心脏彩超心功能相关参数差异无统计学意义(P>0.05);两组不良反应(低血压、肾功能恶化和电解质影响)发生率差异无统计学意义(P>0.05)。随访3个月,两组血浆N-末端脑利钠肽水平、心脏彩超心功能相关参数差异有统计学意义(P<0.05),观察组改善更明显;两组明尼苏达心功能不全生命质量量表评分差异有统计学意义(P<0.05),观察组更低;两组心力衰竭再入院率差异有统计学意义(P<0.05),观察组更少。结论早期应用小剂量沙库巴曲缬沙坦联合rhBNP治疗可显著改善急性前壁心肌梗死介入术后合并心力衰竭患者的心功能,提高生存质量,降低3个月内心力衰竭再入院风险,同时安全性良好。

不同剂量重组人脑利钠肽联合比索洛尔在老年急性心肌梗死患者PCI后的应用对比

目的 比较不同剂量的重组人脑利钠肽(rhBNP)联合比索洛尔在老年急性心肌梗死(AMI)患者经皮冠状动脉介入治疗(PCI)后的应用价值。方法 选取2020年1月—2022年10月秦皇岛市第一医院收治的138例老年AMI患者进行前瞻性研究,按照随机数字表法分为三组,各46例。各组均行PCI和比索洛尔治疗,术前2 h,小剂量组给予1.5μg/(kg·min)的rhBNP,中剂量组给予2.0μg/(kg·min)的rhBNP,大剂量组给予3.0μg/(kg·min)的rhBNP。比较各组治疗前后心功能[左室射血分数(LVEF)、心脏指数(CI)、每分钟搏出量(SV)、血浆脑钠肽(BNP)]、心电生理指标[窦性心搏RR间期标准差(SDNN)、相邻RR间期差值均方根(RMSSD)、低频段/高频段(LF/HF)]、肾功能[血肌酐(Scr)、β2-微球蛋白(β2-MG)、血尿素氮(BUN)]、核因子E2相关因子2/血红素加氧酶-1(Nrf2/HO-1)通路及治疗后不良反应、心血管不良事件的发生情况。结果 治疗72 h后,大剂量组LVEF、CI、SV、SDNN、RMSSD及Nrf2、HO-1蛋白水平均高于中剂量组和小剂量组(P<0.05),大剂量组的血浆BNP水平、LF/HF低于中剂量组和小剂量组(P<0.05);治疗72 h后,中剂量组和小剂量组的心功能、心电生理指标、Nrf2/HO-1信号通路的蛋白比较差异均无统计学意义(P>0.05)。治疗前、治疗72 h后,各组血清Scr、β2-MG、BUN水平比较差异均无统计学意义(P>0.05),各组不良反应总发生率、心血管不良事件的总发生率比较差异均无统计学意义(P>0.05)。结论 rhBNP联合比索洛尔应用于老年AMI患者PCI后疗效确切,大剂量rhBNP可显著改善心功能、心率变异性,可能与激活Nrf2/HO-1通路有关,且对肾功能损害、不良反应及心血管不良事件无明显影响。

维立西呱联合重组人脑利钠肽治疗HFrEF伴心房颤动的临床效果研究

目的研究维立西呱联合重组人脑利钠肽治疗射血分数降低的心力衰竭(HFrEF)伴心房颤动的临床效果。方法本研究为回顾性研究,根据治疗方案不同按1:1配对原则将2022年8月至2023年7月郑州大学第一附属医院收治的124例HFrEF伴心房颤动患者分为对照组和研究组各62例。两组患者均行常规治疗,对照组另给予重组人脑利钠肽治疗,研究组则给予维立西呱联合重组人脑利钠肽治疗,均持续治疗6个月。比较两组患者治疗6个月后的治疗效果,以及治疗前和治疗3个月、6个月后的心功能指标[左心室高峰充盈率(LVPER)、左室射血分数(LVEF)、左心室收缩末期内径(LVESD)]、心肌损伤相关指标[可溶性人基质裂解素(sST2)、N末端脑钠肽前体(NT-proBNP)、心肌肌钙蛋白Ⅰ(cTnⅠ)]、运动耐力[无氧域摄氧量(VO2AT)、峰值公斤摄氧量(VO2max)、最大运动负荷]、预后相关指标[半乳糖凝集素3(Gal-3)、胱抑素C(CysC)、Periostin蛋白、脂肪细胞型脂肪酸结合蛋白4(FABP4)],同时比较两组患者治疗期间的不良反应发生率和6个月内心力衰竭再入院率。结果治疗6个月后,研究组患者的临床总有效率为93.55%,明显高于对照组的80.65%,差异有统计学意义(P<0.05);治疗3个月、6个月后,研究组患者的LVPER、LVEF明显高于对照组,而LVESD明显低于对照组,差异均有统计学意义(P<0.05);治疗3个月、6个月后,研究组患者的sST2、NT-proBNP、cTnⅠ明显低于对照组,差异均有统计学意义(P<0.05);治疗3个月、6个月后,研究组患者的VO2AT、VO2max、最大运动负荷明显高于对照组,差异均有统计学意义(P<0.05);治疗3个月、6个月后,研究组患者的Gal-3、CysC、Periostin蛋白和FABP4明显低于对照组,差异均有统计学意义(P<0.05);6个月内研究组患者的心力衰竭再入院率为20.97%,明显低于对照组的41.94%,差异有统计学意义(P<0.05);研究组患者治疗期间的不良反应发生率为8.06%,略高于对照组的6.45%,但差异无统计学意义(P>0.05)。结论维立西呱联合重组人脑利钠肽治疗HFrEF伴心房颤动疗效确切,安全性高,可减轻心肌损伤,改善心功能,提高运动耐力,预后良好。

重组人脑利钠肽治疗射血分数保留心力衰竭患者的疗效

目的:探讨重组人脑利钠肽治疗射血分数保留心力衰竭患者的疗效和安全性,以及患者用药后sST2及N末端B型利钠肽原(NT-proBNP)水平变化。方法:选取包头市第四医院2020年2月-2022年2月收治射血分数保留心力衰竭患者60例,按照是否接受重组人脑利钠肽治疗分为观察组(联合注射用重组人脑利钠肽治疗)30例及对照组(常规治疗)30例,观察两组治疗前、治疗72 h后,6 min步行试验(6 MWT)、血清sST2和NT-proBNP水平、超声心动图指标及临床疗效。结果:治疗72 h后,观察组6 MWT高于对照组,NT-proBNP水平低于对照组(P<0.05);治疗72 h后,观察组左心房容积指数(LAVI)低于对照组,左心室射血分数(LVEF)升高(P<0.05);观察组总有效率高于对照组(P<0.05);治疗72 h后,观察组血清sST2水平降低(P<0.05)。结论:注射用重组人脑利钠肽可改善射血分数保留心力衰竭患者的心肌功能,增加心脏排血量,减轻心肌细胞损伤,经sST2及NT-proBNP水平评估后确保有效,且临床用药安全性好,建议推广。

芪参益气滴丸联合重组人脑利钠肽治疗射血分数保留的心力衰竭的临床研究

目的:探讨芪参益气滴丸联合重组人脑利钠肽治疗射血分数保留的心力衰竭(HFpEF)的临床效果。方法:选择2023年1—10月九江市第一人民医院收治的69例HFpEF患者。采用随机数字法分为A组、B组与C组,各23例。A组采用抗心力衰竭常规治疗;B组在A组基础上给予芪参益气滴丸治疗,C组在B组基础上给予注射用重组人脑利钠肽治疗。比较三组治疗前后左房径(LA)、左室射血分数(LVEF)、左室短轴缩短率(LVFS)、舒张早期二尖瓣峰值流速及舒张末期二尖瓣峰值流速比值(E/A)、血清氨基末端-B型脑钠肽前体(NT-proBNP)及6分钟步行试验(6MWT)结果,记录三组用药期间不良反应发生率及再住院率。结果:治疗前、治疗6周后,三组LA比较,差异均无统计学意义(P>0.05);治疗6周后,三组NT-proBNP均低于治疗前,LVEF、LVFS、E/A、6MWT均高于治疗前,同时,C组NT-proBNP低于A组与B组,LVEF、LVFS、E/A、6MWT均高于A组与B组,差异均有统计学意义(P<0.05)。三组不良反应发生率比较,差异无统计学意义(P>0.05)。三组再住院率比较,差异有统计学意义(P<0.05);C组再住院率低于A组与B组,差异均有统计学意义(P<0.05)。结论:芪参益气滴丸联合重组人脑利钠肽治疗可有效改善HFpEF患者心功能,提高患者步行能力,降低再住院率,安全性高。

重组人脑利钠肽对急性失代偿性心力衰竭的疗效及相关指标的影响探讨

目的观察重组人脑利钠肽(rhBNP)对急性失代偿性心力衰竭的疗效及相关指标的影响。方法78例急性失代偿性心力衰竭患者,根据治疗方案差异分成对照组与观察组,每组39例。对照组采取常规治疗,观察组在对照组基础上加用重组人脑利钠肽治疗。比较两组治疗前后临床症状评分、炎性介质水平、血管内皮功能、心功能指标及生存质量。结果治疗后,两组呼吸困难、下肢水肿、入睡困难、喘息不止、颈静脉怒张评分较治疗前更低,且观察组呼吸困难、下肢水肿、入睡困难、喘息不止、颈静脉怒张评分分别为(1.05±0.26)、(1.43±0.25)、(0.77±0.21)、(1.51±0.45)、(1.29±0.62)分,较对照组的(2.52±0.89)、(2.31±0.67)、(1.07±0.38)、(2.12±0.36)、(2.31±0.72)分更低(P<0.05)。治疗后,两组肿瘤坏死因子-α、白细胞介素-6、超敏C反应蛋白水平较治疗前更低,且观察组肿瘤坏死因子-α、白细胞介素-6、超敏C反应蛋白水平分别为(0.43±0.15)pg/L、(8.86±1.51)pg/ml、(8.10±1.15)mg/L,较对照组的(0.61±0.11)pg/L、(10.51±1.62)pg/ml、(10.32±1.22)mg/L更低(P<0.05)。治疗后,两组一氧化氮、内皮素-1水平较治疗前更低,且观察组一氧化氮水平(53.81±7.92)μmol/L、内皮素-1水平(40.91±2.30)ng/L较对照组的(60.46±6.42)μmol/L、(52.16±3.63)ng/L更低(P<0.05)。两组治疗后左心室射血分数、心输出量、心脏指数较治疗前更高,左心室舒张末期内径、左心室收缩末期内径较治疗前更小,且观察组左心室射血分数、心输出量、心脏指数较对照组更高,左心室舒张末期内径、左心室收缩末期内径较对照组更小(P<0.05)。两组治疗后生理、心理、社会关系、环境评分较治疗前更高,且观察组较对照组更高(P<0.05)。结论采用重组人脑利钠肽治疗急性失代偿性心力衰竭效果显著,其能够改善患者临床相关症状及血管内皮功能,有助于心功能早日恢复至健康状态。

沙库巴曲缬沙坦联合冻干重组人脑利钠肽治疗心力衰竭的疗效及对NT-proBNP的影响

目的探讨沙库巴曲缬沙坦联合冻干重组人脑利钠肽治疗心力衰竭的疗效及对NT-proBNP的影响。方法选取2022年4月至2023年5月云南省昆明市第一人民医院心内科收治的150例心力衰竭患者为研究对象,根据就诊时间分为两组。参照组采用沙库巴曲缬沙坦治疗,实验组在参照组基础上使用冻干重组人脑利钠肽治疗。对比两组治疗效果、心功能、血浆BNP、NT-proBNP水平及不良反应发生情况。结果实验组治疗总有效率高于参照组,差异有统计学意义(P<0.05)。实验组干预后心率低于参照组,每搏量及LVEF均高于参照组,差异有统计学意义(P<0.05)。实验组干预后血浆BNP、NT-proBNP水平均低于参照组,差异有统计学意义(P<0.05)。实验组不良反应发生率低于参照组,差异有统计学意义(P<0.05)。结论沙库巴曲缬沙坦联合冻干重组人脑利钠肽治疗心力衰竭可显著提高疗效,降低血浆BNP及NT-proBNP水平,改善患者心功能,减少不良反应。